


LEGEND-T2DM Evidence Dissemination Summary

Target: **empagliflozin**, Comparator: **glyburide** Outcome: **Diabetic ketoacidosis** Subgroup: **All**

How Often? (Incidence rates in the PS-matched target cohorts)

| Data source | Persons exposed | Person-time (yrs) | Nr. of outcomes | IR (/1,000 PY) |
|------------------|-----------------|-------------------|-----------------|----------------|
| CCAE | 23,892 | 17,527 | 44 | 2.51 |
| Clinformatics | 26,352 | 18,476 | 49 | 2.65 |
| DA Germany | 3,364 | 2,860 | 0 | 0.00 |
| LDP France | - | - | - | - |
| MDCD | 3,156 | 1,692 | 15 | 8.86 |
| MDCR | 2,690 | 1,540 | <5 | <3.25 |
| Open Claims | 302,022 | 221,082 | 266 | 1.20 |
| Optum EHR | 23,534 | 10,871 | 22 | 2.02 |
| Veterans Affairs | 1,666 | 1,681 | <10 | <5.95 |

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

